The ruling for Mumia Abu-Jamal may lead to similar decisions in favor of other infected prisoners, which could strain prison budgets.
Jim Cramer outlines why investors need to watch Washington to determine if the Trump rally can continue.
The man who originally popularized the "Dogs of the Dow" method in 1991 is looking at five Dow components in particular.
U.S. stocks were lower Thursday as investors digested economic data and looked ahead to 2017.
U.S. stocks turned negative as investors watched the elusive 20,000 mark for the Dow Jones industrial average slip away.
These big winners for the Dow added $92 billion in market value to the pockets of investors, USA Today reports.
The only way to be prepared and ready for the next epidemic is to make vaccines against agents that we know exist.
CNBC's Dominic Chu reports on how dividends turn the Dow's laggards into winners. The "Fast Money" traders weigh in.
U.S. equities fell slightly on Wednesday, with real estate lagging, as the Dow Jones industrial average failed to reach 20,000.
Between when the Dow was trading at the 10,000 level and now, Pfizer, Merck, General Electric, Verizon and Cisco lagged the broader index.
Stocks rose as investors remained unfazed by geopolitical tensions, while the Dow Jones industrial average kept marching toward 20,000.
The Nasdaq 100 hit a fresh all-time intraday high, while the three major indexes closed within 0.75 percent of their record highs.
Jefferies lowers its 2017 Merck earnings-per-share estimate to $3.69 from $4.14.
The pharmaceutical company wins its hepatitis C drug trial against Gilead Sciences.
Some of the names on the move ahead of the open.
Merck was awarded $2.54 billion in royalties by a jury in a patent lawsuit against Gilead Sciences over Gilead's hepatitis C drugs.
Shares of Gilead sink after-hours following a court order to pay Merck $2.5 billion in Hepatitis C royalties. CNBC's Meg Tirrell reports. The "Fast Money" traders weigh in.
Chris Retzler, Needham Growth Fund, and Ronny Gal, Sanford C. Bernstein, discuss buying opportunities amid health care's underperformance. With CNBC's Mike Santoli and Stephanie Link, TIAA Global Asset Management.
CNBC's Dominic Chu takes a look at the stocks that lagged the Dow Jones Industrial Average last year that are now surging ahead.
The U.S. president-elect said he dislikes what has happened to drug prices, and pharma stocks slumped.